FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the use of a peptide with a sequence Ile–Asp–GIn–GIn–Val–Leu–Ser–Arg–Ile–Lys–Leu–Glu–Ile–Lys–Arg–Cys–Leu to prevent occurrence or reduction of incidence of acute retention of urine in mammals, and can be used in medical practice.
EFFECT: disclosed NTP-peptide promotes treatment of undesirable cell proliferation in mammals, particularly benign prostatic hyperplasia.
11 cl, 11 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF REDUCING SEVERITY OR PREVENTING ACERBATION OF PROGRESSION OF SYMPTOMS OF BPH | 2017 |
|
RU2744691C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
